Mycophenolate Mofetil Teva (Mycophenolate Mofetil)

The drug is a pro‑drug that is converted in the body to mycophenolic acid. Mycophenolic acid selectively inhibits the enzyme inosine monophosphate dehydrogenase (IMPDH), which is essential for guanosine nucleotide synthesis in activated T and B lymphocytes. This inhibition blocks DNA synthesis in these cells, reducing their proliferation and suppressing the immune response.

The dosage of Mycophenolate Mofetil Teva is individualized by the prescribing physician based on the specific indication, patient weight, renal function and other clinical factors. The prescriber determines the appropriate strength, frequency and duration of therapy, and patients should follow the written prescription without alteration.

Safety data for Mycophenolate Mofetil in pregnancy are limited and the drug is classified as having unknown pregnancy risk. It is generally avoided in pregnant women because of potential teratogenic effects. Breastfeeding is also not recommended, as the drug can be excreted in milk. Women of child‑bearing potential should use effective contraception and discuss risks with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

The most common alternative to Mycophenolate Mofetil is azathioprine, another antimetabolite. Mycophenolate generally provides more potent and selective inhibition of lymphocyte proliferation with a different side‑effect profile, often resulting in lower rates of certain toxicities such as hepatotoxicity. However, both agents require careful monitoring for bone‑marrow suppression and infection risk.

Mycophenolate Mofetil Teva should be stored at ambient temperature, preferably below 25 °C. Keep the product in its original packaging, protect it from moisture and direct light, and ensure the container is tightly closed. Do not store in a refrigerator or freezer unless specifically instructed by the manufacturer.

The medication is taken orally, usually as whole tablets or capsules. It can be swallowed with water and may be taken with or without food, although taking it with food can reduce gastrointestinal upset for some patients. Doses should be spaced evenly throughout the day as directed by the prescriber.

Serious risks include severe infections due to immune suppression, bone‑marrow suppression leading to neutropenia, anemia or lymphopenia, and an increased long‑term risk of certain malignancies. Patients should promptly report fever, unexplained bruising, persistent diarrhea, or any signs of liver dysfunction, and undergo regular laboratory monitoring as advised by their clinician.

Mycophenolate Mofetil should be avoided in individuals with known hypersensitivity to the drug or its components, in patients with active, uncontrolled infections, and in women who are pregnant or planning to become pregnant without effective contraception. It is also contraindicated in patients with severe renal impairment unless dose adjustments are made under medical supervision.